Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
DNMT3b protects centromere integrity by restricting R-loop-mediated DNA damage
You can also browse our directory of providers already partnering with Strive to find someone who understands what tailored medication regimens can look like for you
Mechanism of Action (Research Context) In controlled research environments, retatrutide has been shown to interact with three key metabolic signalling pathways: GLP-1 receptor activity associated with appetite signalling and glucose regulation GIP receptor activity involved in insulin and fat metabolism Glucagon receptor activity linked to energy expenditure and lipid mobilisation This triple-pathway engagement makes retatrutide of particular interest for metabolic and endocrine research models studying obesity, insulin resistance and energy homeostasis
The toxin resembled glucagon, a hormone that raises blood sugar, so, scientists named it glucagon-like-peptide 1, or GLP-1. In the early 2000s, we got our first medical breakthrough with GLP-1, a drug called exenatide (Byetta) approved for the treatment of type 2 diabetes
